Drug pricing review group raises recommended price for Gilead’s remdesivir

(Reuters) – The Institute for Clinical and Economic Review on Wednesday boosted its benchmark price for Gilead Sciences Inc’s remdesivir, suggesting the antiviral could be priced up to $5,080, based on benefits shown in COVID-19 patients.

The Boston-based group had previously suggested a price of around $4,500 for a 10-day course of remdesivir. Gilead has not announced the price of the therapy in the United States.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)